Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Saphris
Synonyms :
Class :
Antipsychotics, 2nd Generation
Brand Name :
Saphris
Synonyms :
Class :
Antipsychotics, 2nd Generation
Dosage Forms & Strengths
Sublingual tablet
2.5mg
5mg
10mg
5
mg
sublingually
every 12 hrs
a day; maybe increase to 10 mg sublingually 2 times a day
Do not exceed 20 mg per day
Monotherapy:
10 mg sublingually every 12 hours a day; may decrease 5 to 10 mg sublingually every 12 hours a day;
Do not exceed 20 mg/day
Adjunctive Therapy:
5 mg sublingually every 12 hours a day; maybe increase to 10 mg sublingually 2 times a day
Do not exceed 20 mg per day
Monotherapy:
10 mg sublingually every 12 hours a day; may decrease 5 to 10 mg sublingually every 12 hours a day;
Do not exceed 20 mg/day
Adjunctive Therapy:
5 mg sublingually every 12 hours a day; maybe increase to 10 mg sublingually 2 times a day
Do not exceed 20 mg per day
Dosage Forms & Strengths
Sublingual tablet
2.5mg
5mg
10mg
Age: 10-17 years
2.5 sublingually every 12 hours a day; may increase to 5 mg sublingually every 12 hours a day after 3 days and to 10 mg sublingually every 12 hours a day after 3 additional days
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may enhance the concentration of serum when combined with paroxetine
may decrease the serum concentration and decrease in the efficacy
It may enhance sedation when combined with codeine
It may enhance sedation when combined with oxycodone
asenapine and gilteritinib, when used in combination, increase the QTc interval
It may enhance QTc interval when combined with pentamidine
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
It may enhance sedation when combined with tramadol
It may increase the hypotensive effect when combined with antihypertensive agents
It may increase the hypotensive effect when combined with antihypertensive agents
It may increase the hypotensive effect when combined with antihypertensive agents
It may increase the hypotensive effect when combined with antihypertensive agents
It may increase the hypotensive effect when combined with antihypertensive agents
may enhance the concentration of serum when combined with asenapine
may enhance the concentration of serum when combined with asenapine
may enhance the concentration of serum when combined with asenapine
may enhance the concentration of serum when combined with asenapine
may enhance the concentration of serum when combined with asenapine
It may enhance the sedation effect when combined with lumateperone
It may enhance the sedation when combined with tasimelteon
when ajmaline is used together with asenapine, the risk or seriousness of QTc prolongation is enhanced
The potential for increased CNS depression risk or seriousness occurs when asenapine is used together with pipecuronium
When asenapine is used together with bromisoval, the risk or seriousness of CNS depression is enhanced
When captodiame is used together with asenapine, There is a risk or seriousness of CNS depression is enhanced
When asenapine is used together with medazepam, the risk or seriousness of CNS depression is enhanced
When asenapine is used together with niaprazine, the risk or seriousness of CNS depression is enhanced
When asenapine is used together with levosulpiride, the risk or seriousness of CNS depression is enhanced
When asenapine is used together with fluconazole, this leads to reduction in the asenapine metabolism
When chlordiazepoxide is used together with asenapine, this leads to enhanced risk or seriousness of CNS depression
When asenapine is used together with somatotropin, this leads to a rise in asenapine’s metabolism
When asenapine is used together with melitracen, this leads to enhanced risk or seriousness of CNS depression
may diminish the therapeutic effect of the drug
When ponesimod is used together with asenapine, this leads to enhanced risk or seriousness of bradycardia
When asenapine is used together with adenosine, this leads to enhanced risk or seriousness of QTc prolongation
When asenapine is used together with givinostat, this leads to enhanced risk or seriousness of Qtc prolongation
When emylcamate is used together with asenapine, this leads to enhanced risk or seriousness of CNS depression
When asenapine is used together with etizolam, this leads to enhanced risk or seriousness of CNS depression
When asenapine is used in combination with profenamine, this leads to reduction in therapeutic effectiveness of profenamine
asenapine: it may increase the risk of hypotension with caroverine
the therapeutic effectiveness of insulin aspart can be decreased when used in conjunction with asenapine
asenapine: it may increase the risk of CNS depression with dextropropoxyphene
the hazard or seriousness of QTc prolongation can be heightened when digitoxin is combined with asenapine
When asenapine is used together with diazoxide, this leads to reduction in diazoxide’s antihypertensive effects
QTc interval is increased both by lenvatinib and asenapine
serotonergic Agents may enhance the adverse/toxic effect of antipsychotic Agents
antipsychotic agents may enhance the adverse/toxic effect of amphetamines
antipsychotic agents may enhance the adverse/toxic effect of amphetamines
antipsychotic agents may enhance the adverse/toxic effect of amphetamines
it enhances by affecting the hepatic enzyme CYP2C9 metabolism
it enhances by affecting the hepatic enzyme CYP2D6 metabolism
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
May diminish the effects of ketoprofen by pharmacodynamic antagonism
may diminish the effects of indomethacin by pharmacodynamic antagonism
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
insulin degludec/insulin aspart
may decrease the effect of each other
may enhance the risk of adverse/toxic effect of antipsychotic agents
may enhance the risk of adverse/toxic effect of antipsychotic agents
may enhance the risk of adverse/toxic effect of antipsychotic agents
may enhance the risk of adverse/toxic effect of antipsychotic agents
may decrease the absorption of antipsychotic agents
may decrease the absorption of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the risk of adverse effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may enhance the concentration of serum when combined with asenapine
may have an increased effect of CNS depression when combined with Asenapine
asenapine has the ability to reduce the absorption of ferrous succinate, which can lower serum levels and perhaps compromise efficacy
the risk of depression in the central nervous system can be enhanced when dihydrocodeine is taken with asenapine
combining asenapine with indalpine may increase the chances of adverse effects
the risk of hypertension may be increased
the therapeutic effects of racepinephrine may be reduced
the risk of CNS depression may be increased
When asenapine is used together in combination with profenamine, this leads to reduction in therapeutic effectiveness of profenamine
Adverse drug reactions:
>10%
Headache (12%)
Dizziness (11%)
Somnolence (24%)
Pediatric patients
Somnolence (49%)
Oral paraesthesia (27%)
1-10%
Akathisia (4%)
Oral hypoesthesia (4%)
Dry mouth (3%)
Dysgeusia (3%)
Insomnia (6%)
Weight gain (5%)
Dyspepsia (4%)
Anxiety (4%)
Fatigue (4%)
Pregnancy warnings:
AU TGA pregnancy category: C
US FDA pregnancy category: N/A
Lactation:
Excreted into human milk is UNknown
Pregnancy Categories:
Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first or later trimester.
Category B: No evidence shown of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for a result in humans must take care of potential risks in pregnant women
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Patient Information Leaflet
Generic Name: asenapine
Why do we use asenapine?
asenapine are an Antipsychotics, 2nd Generation used to treat Schizophrenia and bipolar disorder.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
